{
    "clinical_study": {
        "@rank": "13158", 
        "arm_group": {
            "arm_group_label": "docetaxel, cisplatin and S-1 (DCS)", 
            "arm_group_type": "Experimental", 
            "description": "All patients receive the combination therapy of docetaxel, cisplatin and S-1 for a maximum of 6 cycles. Docetaxel 60mg/m2 IV infusion over 1 hour on d1; Cisplatin 30mg/m2 IV infusion on d1,2; S-1 40mg orally twice a day for patients with the body surface area (BSA) less than 1.25m2, 50mg twice a day with the BSA between 1.25 and 1.5m2, 60mg twice a day with the BSA over 1.5m2."
        }, 
        "brief_summary": {
            "textblock": "The combination of Cisplatin and S-1 (CS) achieved a response rate of approximately 45% with\n      the PFS being around 6 months and overall survival time being 13 months in Japanese and\n      Chinese gastric patients. It remains unclear whether the addition of docetaxel to CS would\n      further enhance the efficacy as it dose in DCF(docetaxel, cisplatin and 5-fluorouracil).\n      This is a single center, phase II clinical trial to  evaluate the efficacy of docetaxel,\n      cisplatin and S-1 (DCS) as first line chemotherapy for patients with advanced gastric and\n      gastroesophageal junction cancer."
        }, 
        "brief_title": "Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Gastric Cancer", 
            "Gastroesophageal Junction Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a single arm trial. All Patients will receive up to 6 cycles of triple chemotherapy\n      with docetaxel, cisplatin and S-1. Given the severe toxicity of DCF regimen, here the total\n      dose of docetaxel and cisplatin is both reduced to 60mg/m2. For patients with CR/PR/SD\n      disease after 6 cycles of chemotherapy, maintenance therapy with S-1 are recommended.\n      Antitumor activity will be evaluated every two cycles according to RECIST1.1."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed unresectable advanced gastric or\n             gastroesophageal junction cancer;\n\n          -  No previous chemotherapy and radiation for advanced disease except palliative\n             radiation for a local pain control;\n\n          -  At least one evaluable lesion per RECIST (Response Evaluation Criteria in Solid\n             Tumors) 1.1;\n\n          -  ECOG (Eastern Cooperative Oncology Group) performance status 0-1;\n\n          -  Recovery from the toxicities of previous therapy;\n\n          -  Adequate bone marrow and organ function. Hb\u22658 G/L; Absolute neutrophil \u2265 2.0 G/L; PLT\n             \u2265100 G/L ;ALT/AST \u22641.5 ULN or \u22645ULN with liver metastases; TBIL \u22641.5 ULN; Cr\u22641.0 ULN;\n\n          -  Life expectancy \u22653 months;\n\n          -  For men and women of childbearing potential, agree on taking effective contraceptive\n             method of birth control from the signed informed consent until 3 months after the\n             last study drug administration;\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Pathology type other than adenocarcinoma,such as squamous cell carcinoma;\n\n          -  Previous treatment with taxanes, cisplatin or S-1;\n\n          -  Relapse within 6 months after the end of adjuvant chemotherapy;\n\n          -  Known brain metastases;\n\n          -  Complete or incomplete intestinal obstruction or uncontrolled gastrointestinal\n             bleeding;\n\n          -  Known deficiency of DPD enzyme;\n\n          -  Kown HIV infecton or drug addiction;\n\n          -  Any acute or chronic medical or psychiatric condition that would make the patient\n             inappropriate for entry into this trial in the judgement of investigators;\n\n          -  Myocardial infarction within 6 months prior to the entry of this trial;\n\n          -  Known history of allergic reaction to taxanes and platinum;\n\n          -  Pregnant or breast feeding women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747707", 
            "org_study_id": "CH-GI-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "docetaxel, cisplatin and S-1 (DCS)", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "taxotere"
            }, 
            {
                "arm_group_label": "docetaxel, cisplatin and S-1 (DCS)", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "docetaxel, cisplatin and S-1 (DCS)", 
                "intervention_name": "S-1", 
                "intervention_type": "Drug", 
                "other_name": "TS-1"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "gastric cancer", 
            "gastroesophageal junction cancer", 
            "chemotherapy", 
            "docetaxel", 
            "cisplatin", 
            "S-1"
        ], 
        "lastchanged_date": "December 10, 2012", 
        "location": {
            "contact": {
                "email": "hsunyk@tom.com", 
                "last_name": "Yongkun Sun, M.D", 
                "phone": "8610-87788145"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "10021"
                }, 
                "name": "Cancer Hospital & Institute, Chinese Academy of Medical Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Clinical Trial of Cisplatin,Docetaxel and S-1 as First Line Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer", 
        "overall_contact": {
            "email": "zhouap1825@126.com", 
            "last_name": "Aiping Zhou, M.D", 
            "phone": "8610-87788145"
        }, 
        "overall_contact_backup": {
            "email": "hsunyk@tom.com", 
            "last_name": "Yongkun Sun, M.D", 
            "phone": "8610-87788145"
        }, 
        "overall_official": {
            "affiliation": "Cancer Hospital & Institute, Chinese Academy of Medical Sciences", 
            "last_name": "Aiping Zhou, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: State Food and Drug Adminstration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the OS of DCS in patients with chemo-naive, advanced gastric or gastroesophageal junction cancer.", 
            "measure": "overall survival time (OS)", 
            "safety_issue": "No", 
            "time_frame": "14 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747707"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Aiping Zhou", 
            "investigator_title": "Associate professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the PFS of DCS in patients with chemo-naive, gastric or gastroesophageal junction cancer", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To determine the tolerability of DCS in patients with chemo-naive, gastric or gastroesophageal junction cancer.", 
                "measure": "safety profile", 
                "safety_issue": "Yes", 
                "time_frame": "4 months"
            }
        ], 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}